Overview

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone. The purpose of the first phase of this study is to determine the best dose of RAD001 given with Nexavar®, and to see what effects, good and/or bad, the study drug has on the subject and the subject's tumor. This study will also observe side effects experienced by the subject.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute
The Methodist Hospital System
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Niacinamide
Sirolimus
Sorafenib